BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 29702017)

  • 1. Is Prostate Imaging Reporting and Data System Version 2 Sufficiently Discovering Clinically Significant Prostate Cancer? Per-Lesion Radiology-Pathology Correlation Study.
    Lee MS; Moon MH; Kim YA; Sung CK; Woo H; Jeong H; Son H
    AJR Am J Roentgenol; 2018 Jul; 211(1):114-120. PubMed ID: 29702017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
    Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
    AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer.
    Seo JW; Shin SJ; Taik Oh Y; Jung DC; Cho NH; Choi YD; Park SY
    AJR Am J Roentgenol; 2017 Jul; 209(1):W1-W9. PubMed ID: 28418690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
    Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
    AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI in 518 patients: based on PI-RADSv2 and using whole-mount histopathology reference.
    Mohammadian Bajgiran A; Afshari Mirak S; Shakeri S; Felker ER; Ponzini D; Ahuja P; Sisk AE; Lu DS; Raman SS
    Abdom Radiol (NY); 2019 Mar; 44(3):1052-1061. PubMed ID: 30460528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis.
    Woo S; Suh CH; Kim SY; Cho JY; Kim SH
    Eur Urol; 2017 Aug; 72(2):177-188. PubMed ID: 28196723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.
    Vargas HA; Hötker AM; Goldman DA; Moskowitz CS; Gondo T; Matsumoto K; Ehdaie B; Woo S; Fine SW; Reuter VE; Sala E; Hricak H
    Eur Radiol; 2016 Jun; 26(6):1606-12. PubMed ID: 26396111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive role of PI-RADSv2 and ADC parameters in differentiating Gleason pattern 3 + 4 and 4 + 3 prostate cancer.
    Alessandrino F; Taghipour M; Hassanzadeh E; Ziaei A; Vangel M; Fedorov A; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2019 Jan; 44(1):279-285. PubMed ID: 30066169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treatment according to PRIAS.
    Park JJ; Park BK
    J Magn Reson Imaging; 2017 Jun; 45(6):1753-1759. PubMed ID: 27783436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the Prostate Imaging Reporting and Data System, Version 2, on MRI Diagnosis for Extracapsular Extension of Prostate Cancer.
    Matsuoka Y; Ishioka J; Tanaka H; Kimura T; Yoshida S; Saito K; Fujii Y; Kihara K
    AJR Am J Roentgenol; 2017 Aug; 209(2):W76-W84. PubMed ID: 28570124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
    Felker ER; Raman SS; Margolis DJ; Lu DSK; Shaheen N; Natarajan S; Sharma D; Huang J; Dorey F; Marks LS
    AJR Am J Roentgenol; 2017 Dec; 209(6):1272-1277. PubMed ID: 28858541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.
    Song W; Bang SH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Kim CK; Lee HM
    Clin Genitourin Cancer; 2018 Aug; 16(4):281-287. PubMed ID: 29550198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy and Interobserver Agreement for Prostate Imaging Reporting and Data System, Version 2, for the Characterization of Lesions Identified on Multiparametric MRI of the Prostate.
    Purysko AS; Bittencourt LK; Bullen JA; Mostardeiro TR; Herts BR; Klein EA
    AJR Am J Roentgenol; 2017 Aug; 209(2):339-349. PubMed ID: 28570099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic Contrast-Enhanced MRI-Upgraded Prostate Imaging Reporting and Data System Version 2 Category 3 Peripheral Zone Observations Stratified by a Size Threshold of 15 mm.
    Abreu-Gomez J; Krishna S; Narayanasamy S; Flood TA; McInnes MDF; Schieda N
    AJR Am J Roentgenol; 2019 Oct; 213(4):836-843. PubMed ID: 31120786
    [No Abstract]   [Full Text] [Related]  

  • 15. 3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard.
    Asvadi NH; Afshari Mirak S; Mohammadian Bajgiran A; Khoshnoodi P; Wibulpolprasert P; Margolis D; Sisk A; Reiter RE; Raman SS
    Abdom Radiol (NY); 2018 Nov; 43(11):3117-3124. PubMed ID: 29725743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI-RADS version 2: Preoperative role in the detection of normal-sized pelvic lymph node metastasis in prostate cancer.
    Park SY; Shin SJ; Jung DC; Cho NH; Choi YD; Rha KH; Hong SJ; Oh YT
    Eur J Radiol; 2017 Jun; 91():22-28. PubMed ID: 28629566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer.
    Nougaret S; Robertson N; Golia Pernicka J; Molinari N; Hötker AM; Ehdaie B; Sala E; Hricak H; Vargas HA
    Abdom Radiol (NY); 2017 Jul; 42(7):1968-1974. PubMed ID: 28258355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
    Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
    AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
    [No Abstract]   [Full Text] [Related]  

  • 19. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
    Tosun M; Uslu H
    Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.
    Schwen ZR; Mamawala M; Tosoian JJ; Druskin SC; Ross AE; Sokoll LJ; Epstein JI; Carter HB; Gorin MA; Pavlovich CP
    BJU Int; 2020 Sep; 126(3):373-378. PubMed ID: 32367635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.